Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Progressed on First Line Therapy

EGFR +
- Progressed On EGFR TKI

EGFR 19 or 21

LUN0128
Phase II
Open-Label
Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Advanced or Metastatic Solid Tumors Including EGFR-mutated NSCLC
- PI: Neal Sponsor: Janssen Research
LUN0130
Phase III
Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Advanced NSCLC and Other Solid Tumors (ALGOVE-1)
- PI: Neal Sponsor: Janssen Research & Development, LLC

LUN0122
Phase IIb
JNJ-73241927 (Lazertinib) Monotherapy or in Combo w/ JNJ-81186372 in Advanced NSCLC
- PI: Myall Sponsor: Genentech, Inc.

LUN0123
Phase III Study of the Selective RET Inhibitor TAS0063/HM06 in Advanced Solid Tumors with RET Gene Abnormalities
- PI: Wakelee Sponsor: Helsinn Healthcare SA

LUN0129
Phase III Study of Highly Selective ROS1 Inhibitor NVL-520 in Advanced NSCLC and Other Solid Tumors (ARROS-1)
- PI: Neal Sponsor: Nuvant, Inc.

ALK +
- LUN0130

RET +
- LUN0123

KRAS G12 C +
- None at This Time.

MET/RET/ROS1
- None at This Time.

ROS1 +

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu